Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) FCF Margin (2022 - 2025)

Historic FCF Margin for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to 33.94%.

  • TriSalus Life Sciences' FCF Margin rose 1159600.0% to 33.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 55.12%, marking a year-over-year increase of 1121500.0%. This contributed to the annual value of 139.95% for FY2024, which is 1364600.0% up from last year.
  • TriSalus Life Sciences' FCF Margin amounted to 33.94% in Q3 2025, which was up 1159600.0% from 64.45% recorded in Q2 2025.
  • Over the past 5 years, TriSalus Life Sciences' FCF Margin peaked at 33.94% during Q3 2025, and registered a low of 583.23% during Q3 2022.
  • Its 4-year average for FCF Margin is 208.88%, with a median of 169.32% in 2024.
  • Over the last 5 years, TriSalus Life Sciences' FCF Margin had its largest YoY gain of 2706700bps in 2024, and its largest YoY loss of 178500bps in 2024.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' FCF Margin stood at 263.92% in 2022, then skyrocketed by 37bps to 166.91% in 2023, then skyrocketed by 58bps to 69.69% in 2024, then soared by 51bps to 33.94% in 2025.
  • Its last three reported values are 33.94% in Q3 2025, 64.45% for Q2 2025, and 57.3% during Q1 2025.